Drug intelligence / Profile preview

Org 28611

Development stage: Phase 2
Lead developer: Organon
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration: Intravenous

Overview

Org 28611 (SCH-900111) is a potent, water-soluble synthetic cannabinoid receptor agonist developed by Organon International. It acts as a full agonist at both the cannabinoid CB1 and CB2 receptors. The drug was designed to be suitable for intravenous use, with primary indications as an analgesic and sedative. Org 28611 progressed to Phase II clinical trials in humans for these uses; however, its efficacy was not favorable compared to standard drugs such as midazolam (for sedation) and morphine (for analgesia). As a result, development was discontinued[1][2][4][5][8].

Other names: ORG-28611 hydrochlorideORG28611 hydrochlorideORG 28611 hydrochloride

Targets

CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on Org 28611.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Org 28611.

Explore the full profile